In this video, Gary Lemack, MD, offers a brief overview of overactive bladder treatments in development and explains their significance for providers and patients.
Gary Lemack, MD, of UT Southwestern Medical Center in Dallas, co-authored an article in the April 2020 issue of Urology Times® regarding how the development of new pharmacological and device-based treatments could change the management of overactive bladder. In this interview, Dr. Lemack offers a brief overview of treatments in development and explains their significance for providers and patients.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.